Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 15;11:615972. doi: 10.3389/fphar.2020.615972

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Han, Guo, Zheng, Zhang, De, Xu, Zhang, Sun, Lv, Liang, Xu, Pang and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

IL-6 signaling pathway and inhibitory agents. IL-6 binds to mIL-6R (①) or sIL-6R (②), which triggers the dimerization of transmembrane gp130, followed by the activation of JAK which induces intracellular signaling including MAPK and STAT signaling pathways, and the activation of the SRC family kinase (YES, SRC), with the YES-associated protein signaling pathway subsequently induced. Three types of antibodies have been applied clinically against IL-6 signaling including anti-IL-6 (siltuximab), anti-IL-6R (tocilizumab, sarilumab), and anti-JAK (baricitinib, ruxolitinib) monoclonal antibodies.